Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Hereditary angioedema (HAE): US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Hereditary angioedema: the short answer

The US FDA has approved six medicines covered on this page for hereditary angioedema, each for a specific group of patients: Takhzyro, Andembry, Dawnzera, Cinryze, Ekterly and Kalbitor. On 17 October 2026, three of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Takhzyro, Andembry, Dawnzera, Cinryze, Ekterly and Kalbitor.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is hereditary angioedema?

Hereditary angioedema is a disorder that causes repeated episodes of severe swelling. The swelling most often affects the limbs, face, intestinal tract and airway. Minor trauma or stress may trigger an attack, but swelling often happens without a known trigger.[1]

Attacks in the gut cause severe abdominal pain, nausea and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction. Symptoms typically begin in childhood and worsen during puberty. Untreated, people have attacks every 1 to 2 weeks on average, lasting about 3 to 4 days.[1]

Hereditary angioedema is estimated to affect 1 in 50,000 people worldwide, and most cases are due to C1 inhibitor deficiency. Medicines are used either to prevent attacks or to treat an attack once it starts.[1, 2, 3]

Hereditary angioedema in the Gulf

A 2023 study described the phenotypic and genotypic characterization of hereditary angioedema in Saudi Arabia, and a 2023 Delphi initiative produced a consensus on HAE diagnosis and management in the Middle East.[4, 5]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 3 of 6 were listed in Saudi Arabia and 3 of 6 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[6, 7]

US FDA-approved medicines for hereditary angioedema

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Takhzyro (lanadelumab-flyo)
    US FDA-approved for prevention of HAE attacks in adults and children 2 years and older. It is an injection under the skin.[2]
    Current US label version: 18 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
  • Andembry (garadacimab-gxii)
    US FDA-approved for prevention of HAE attacks in adults and children 12 and older. It is a monthly injection under the skin that blocks activated factor XII.[8]
    Current US label version: 30 June 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Kuwait, Turkey, Pakistan
  • Dawnzera (donidalorsen)
    US FDA-approved for prevention of HAE attacks in adults and children 12 and older. It is an injection under the skin.[9]
    Current US label version: 31 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, Qatar, Bahrain, Egypt, Jordan, Lebanon
  • Cinryze (C1 esterase inhibitor (human))
    US FDA-approved for routine prevention of angioedema attacks in adults, adolescents and children 6 and older with HAE. It is a C1 esterase inhibitor given into a vein.[10]
    Current US label version: 28 November 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
  • Ekterly (sebetralstat)
    US FDA-approved for treatment of acute HAE attacks in adults and children 12 and older. It is a tablet taken by mouth.[3]
    Current US label version: 1 April 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Bahrain
  • Kalbitor (ecallantide)
    US FDA-approved for treatment of acute HAE attacks in patients 12 and older. It is an injection under the skin given by a healthcare provider.[11]
    Current US label version: 1 July 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
    Country access guides: Saudi Arabia, Qatar, Oman, Jordan

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[12, 13] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for hereditary angioedema

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for hereditary angioedema?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Takhzyro, Andembry, Dawnzera, Cinryze, Ekterly and Kalbitor. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Takhzyro available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Takhzyro?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

What is the difference between prevention and on-demand HAE medicines?

Preventive medicines such as Takhzyro, Andembry, Dawnzera and Cinryze are used regularly to reduce attacks. On-demand medicines such as Ekterly and Kalbitor treat an attack once it starts.

Sources for the condition-specific answers: [2, 8, 9, 10, 3, 11]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. MedlinePlus Genetics (US National Library of Medicine): Hereditary angioedema
  2. DailyMed: TAKHZYRO (lanadelumab-flyo) US prescribing information, label version 18 September 2026
  3. DailyMed: EKTERLY (sebetralstat) US prescribing information, label version 1 April 2026
  4. Sheikh F, et al. Phenotypic and Genotypic Characterization of Hereditary Angioedema in Saudi Arabia. J Clin Immunol. 2023 (PubMed 36348183)
  5. Maurer M, et al. Consensus on diagnosis and management of Hereditary Angioedema in the Middle East: A Delphi initiative. World Allergy Organ J. 2023 (PubMed 36601261)
  6. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  7. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  8. DailyMed: ANDEMBRY (garadacimab-gxii) US prescribing information, label version 30 June 2025
  9. DailyMed: DAWNZERA (donidalorsen) US prescribing information, label version 31 August 2026
  10. DailyMed: CINRYZE (C1 esterase inhibitor (human)) US prescribing information, label version 28 November 2025
  11. DailyMed: KALBITOR (ecallantide) US prescribing information, label version 1 July 2025
  12. SFDA: Special Access Program (SAP) guidance, version 1.0
  13. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp